GILEAD SCIENCES, INC. vs Novartis AG, two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where GILD and NVS diverge most: on operating margin, GILD reads -133.2% and NVS reads 32.4%; on net margin, GILD reads -10.6% and NVS reads 25.6%. The rest of the comparable metrics sit closer together. The bull and bear cases for each are in their full reports below.
| Metric | GILD | NVS |
|---|---|---|
| Price | $151.17 | $143.71 |
| Market cap | $187.9B | $278.7B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | — | +0.5% |
| P/E | — | 19.9 |
| P/B | 15.89 | 5.99 |
| P/S | 6.17 | 5.11 |
| EV/EBITDA | 19.4 | 14.4 |
| Revenue growth | +5.6% | +6.4% |
| Gross margin | — | 78.8% |
| Operating margin | -133.2% | 32.4% |
| Net margin | -10.6% | 25.6% |
| Return on equity | -27.4% | 30.0% |
| Return on assets | -6.6% | 12.6% |
| Return on invested capital | 21.8% | 31.8% |
| FCF yield | 6.9% | 6.3% |
| Dividend yield | 2.1% | — |
| Debt / equity | 2.22 | 0.02 |
| Current ratio | 1.27 | 1.12 |
| Altman Z (solvency) | 6.06 | 3.65 |
| Piotroski F (quality) | 4 / 9 | 8 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.